News
Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.
Patient centricity has rapidly gone from a fringe idea to a fundamental principle across the industry, but are pharma companies missing ... patient organisations are front-line for patient support.
Telix continues to investigate TLX101 in front-line and recurrent settings ... U.S. Food and Drug Administration (FDA) in Q4 2024, the company is also on track to submit an IND application ...
Getting a clear view of which companies are really 'walking the talk' in pharma and delivering meaningful ... company remains a leader in front-line therapy in type 1 diabetes and has a ...
Oakmark International Small Cap Strategy’s return was 8.15% (net) for the reporting period. This compares to the MSCI World ...
Hosted on MSN28d
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?A medical scientist in a lab coat gazing at a microscopic view of ... the company is positioning itself for major growth soon. On the financial front, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ...
Will Robinson, program director, LogiPharma, explains how artificial intelligence and sustainability are driving a clear shift in priorities across the pharmaceutical supply ... On the sustainability ...
14d
Investor's Business Daily on MSNTrump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
In 2024, US pharmaceutical imports reached $213 billion, with India providing over 45% of generic drugs and 15% of biosimilars. The move aims to bolster domestic production, raising concerns for ...
For instance, if tariffs are applied at a fixed rate across all the countries, Indian pharma companies could have an edge because of their cost advantage. India accounts for about 50% of generics ...
Many major Indian pharmaceutical companies, including Dr Reddy's, Sun Pharma, and Aurobindo, derive 40-45% of their revenues from the US market, making them particularly vulnerable to any adverse ...
PARIS, April 15 (Reuters) - Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results